Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
Open Access
- 4 June 2020
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (3), 894-898
- https://doi.org/10.3324/haematol.2020.252569
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaBlood, 2019
- Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)Expert Opinion on Investigational Drugs, 2017
- Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*American Journal of Hematology, 2017
- Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscapeLeukemia, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous LeukemiaCancer Discovery, 2016
- Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML CellsClinical Cancer Research, 2016
- The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphomaBlood, 2015
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaBlood, 2010
- Induction therapy for elderly patients with acute myeloid leukemiaBlood Reviews, 2008